mortality/aging
• 50% of mice die by 45 weeks; survival is increased relative to MRL-Faslpr mice
|
immune system
N |
• TNF alpha production is not significantly different from Faslpr, Irf1-sufficient mice
|
• at 12 weeks, splenic CD4+CD25+ T cells are increased in percentage compared to wild-type MRL-Faslpr mice; percentage increases from 27.1% at 8 weeks to 40.3% at 26 weeks in wild-type mice, double mutants have 60.6% at 26 weeks
• 26 week old mice have a percentage of CD4+CD25+CD62L+ T cells (32.2%) compared to wild-type MRL-Faslpr mice (13.1%)
|
• mesangial cells from 8- and 26-week old mice show significantly less Il12 production than Faslpr, Irf1-sufficient cells upon stimulation with LPS and interferon gamma
|
• levels of anti-dsDNA IgG2a are significantly decreased relative to Faslpr, Irf1-sufficient mice
|
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes
|
hematopoietic system
• at 12 weeks, splenic CD4+CD25+ T cells are increased in percentage compared to wild-type MRL-Faslpr mice; percentage increases from 27.1% at 8 weeks to 40.3% at 26 weeks in wild-type mice, double mutants have 60.6% at 26 weeks
• 26 week old mice have a percentage of CD4+CD25+CD62L+ T cells (32.2%) compared to wild-type MRL-Faslpr mice (13.1%)
|
renal/urinary system
• at 26 weeks of age, mice show much less severe renal disease including IgG and C3 glomerular deposition compared to Faslpr homozygotes
|
homeostasis/metabolism
N |
• only 1 mouse had abnormal urine protein levels (above 200 mg/dl) at 24 weeks of age
|
cellular
• in response to LPS + IFN gamma stimulation, mesangial cells show significantly lower activation than cells from MRL-Faslpr mice
|
integument
N |
• mice do not show characteristic signs of skin disease; at 26 weeks of age, 7/10 mice show no skin involvement, while 3 show minimal skin irritation, compared to 8/10 Faslpr, Irf1 sufficient mice displaying moderate to severe skin involvement
|